Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Sep 16:S2405-8033(25)00204-3.
doi: 10.1016/j.trecan.2025.08.006. Online ahead of print.

Optimizing mitochondria function in immune cells: implications for cancer immunotherapy

Affiliations
Review

Optimizing mitochondria function in immune cells: implications for cancer immunotherapy

Huiyu Li et al. Trends Cancer. .

Abstract

The tumor microenvironment (TME) imposes profound metabolic and functional constraints on immune cells, with mitochondrial dysfunction emerging as a pivotal driver of immunosuppression. While mitochondrial metabolism is well recognized for its role in energy production and cellular homeostasis, its dynamic regulation of immune cell activation, differentiation, and exhaustion within the TME remains underexplored. In this review we summarize insights into how TME stressors such as hypoxia, nutrient competition, and metabolic byproducts subvert mitochondrial dynamics, redox balance, and mitochondrial DNA (mtDNA) signaling in T cells, natural killer (NK) cells, and macrophages, thereby directly impairing their antitumor efficacy. We emphasize that the restoration of mitochondrial fitness in immune cells, achieved by targeting metabolites in the TME and mitochondrial quality control, represents a pivotal axis for adoptive cell therapies (ACTs) and TME reprogramming.

Keywords: ROS; chimeric antigen receptor (CAR); metabolism; mitochondria; tumor immunotherapy.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests J.C. is a co-founder and shareholder of TargTex S.A. – Targeted Therapeutics for Glioblastoma Multiforme. J.C. is a member of the Global Burden Disease (GBD) consortium of the Institute for Health Metrics and Evaluation (IHME), University of Washington (US) and is on the Scientific Advisory board of Vector Bioscience Cambridge. The other authors have no conflicts of interest to declare.

LinkOut - more resources